SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGooch & Housego Regulatory News (GHH)

Share Price Information for Gooch & Housego (GHH)

Share Price is delayed by 15 minutes
Get Live Data
992.00    44.00 (4.64%)
Bid:
972.00
Ask:
988.00
Spread: 16.00 (1.646%)
Market Cap: £271.52m
GHH Live PriceLast checked at - London Stock Exchange

Intraday Gooch & Housego Share Chart

Trading Update

2 Sep 2020 07:00

RNS Number : 7412X
Gooch & Housego PLC
02 September 2020
 

For immediate release

2 September 2020

 

 

Gooch & Housego PLC

("G&H" or the "Company")

 

Trading Update

 

"Trading in line with expectations"

Gooch & Housego PLC (AIM: GHH), the specialist manufacturer of photonic components & systems, provides an update for the 10 months ended 31 July 2020. Overall, trading remains in line with management's expectations for the full year ending 30 September 2020.

Trading

The Group's manufacturing locations in the UK, USA and China are now fully open, thanks to measures that were quickly and efficiently put in place by our site teams, minimising the disruption of the COVID-19 pandemic for our customers whilst keeping our employees safe. Most recently, our Torquay site in the UK has returned to full capacity.

Trading levels in June and July reflected the recovery in the Company's manufacturing capacity and some of our larger customers' manufacturing sites reopening.

Orders for fibre optics, hi- reliability fibre couplers for undersea cables and our A&D and life science capabilities remain robust. There continues to be improved demand for medical diagnostics, in particular for ventilator systems. As previously communicated, industrial laser demand remains at below "normalised" levels, although the semiconductor subsector has demonstrated sustained improvement.

The previously announced cost control measures have been implemented and will support the Group's profitability in H2 FY '20 and beyond.

Priorities in the COVID-19 emergency

Our primary concern during the emergency is the health and safety of our staff, customers and suppliers. Extensive measures have been put in place at all of our sites to ensure we rigorously meet social distancing and cleanliness requirements and all other relevant guidelines and regulations.

Financial strength

The Company remains in a good financial position with a strong balance sheet and liquidity levels that have continued to improve during the period. Total headroom increased to £28.1 million; this included a $10 million extension to the Group's revolving credit facility taking the total to $50 million, as announced in April 2020.

Outlook

There remains significant global economic uncertainty due to the COVID-19 emergency in the short term. That said, our telecommunications, A&D and life sciences businesses have held up well during the period, though the timing and pace of the industrial laser market recovery remains difficult to predict.

Improved industrial laser demand will be driven by technical innovation such as 5G and new laser based manufacturing techniques. There remains substantial long term growth potential for our photonic technologies and system capabilities in all of our target sectors.

The streamlining of our manufacturing sites is on schedule and will deliver the profit improvements previously announced.

 

Mark Webster, Chief Executive Officer of Gooch and Housego, commented:

"We are proud of the way that our staff and management have responded to the COVID-19 emergency. All of our sites in the UK, USA and China are now open and fully compliant with all relevant health and safety requirements. This has been achieved, quickly, efficiently and most importantly, safely.

"While there remains considerable short term economic uncertainty our order book remains robust, the Company's balance sheet has strengthened during the period and we have continued to invest in our high priority R&D targets.

"The COVID-19 emergency has validated G&H's long term strategy of diversification and moving up the value chain. We will continue to pursue this policy through internal investment and where appropriate, acquisitions."

 

 

 

 

For further information contact: -

 

Mark Webster/Chris Jewell

Gooch & Housego PLC

01460 256440

Mark Court/ Charlotte Slater

Buchanan

020 7466 5000

Chris Baird/Patrick Robb/

David Anderson

Investec Bank plc

020 7597 5970

 

Notes to editors

 

1. Gooch & Housego is a photonics technology business headquartered in Ilminster, Somerset, UK with operations in the USA and Europe. A world leader in its field, the company researches, designs, engineers and manufactures advanced photonic systems, components and instrumentation for applications in the Aerospace & Defence, Industrial, Life Sciences and Scientific Research sectors. World leading design, development and manufacturing expertise is offered across a broad range of complementary technologies.

 

2. All financial information included in this announcement is sourced from unaudited management accounts and excludes any specific items. This announcement contains certain forward-looking statements that are based on management's current expectations or beliefs as well as assumptions about future events. These are subject to risk factors associated with, amongst other things, the economic and business circumstances occurring from time to time in the countries and sectors in which G&H operates. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a wide range of variables which could cause actual results, and G&H's plans and objectives, to differ materially from those currently anticipated or implied in the forward-looking statements. Investors should not place undue reliance on any such statements. Nothing in this announcement should be construed as a profit forecast.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSSDESFESSEFU
Date   Source Headline
3rd Jun 20267:00 amRNSDirectorate change
2nd Jun 20267:00 amRNSInterim Results
20th May 20267:00 amRNSNotice of Half Year Results
10th Apr 20262:25 pmRNSHolding(s) in Company
9th Apr 20267:00 amRNSHalf Year Trading Update
20th Mar 20263:16 pmRNSHolding(s) in Company
27th Feb 20262:23 pmRNSResult of AGM
27th Feb 20267:00 amRNSAGM Trading Update
2nd Feb 20267:00 amRNSChief Financial Officer appointment date
22nd Jan 20262:26 pmRNSHolding(s) in Company
13th Jan 20264:41 pmRNSHolding(s) in Company
12th Jan 20264:34 pmRNSPDMR notice
12th Jan 20263:30 pmRNSGrant of LTIP awards
9th Jan 20267:00 amRNSPDMR Notice and Issue of Equity
7th Jan 20267:00 amRNSPosting of Annual Report and Notice of AGM
12th Dec 20257:00 amRNSAppointment of Chief Financial Officer
2nd Dec 202511:36 amRNSDirector/PDMR Shareholding
2nd Dec 20257:00 amRNSResults for the year ended 30 September 2025
25th Nov 20257:00 amRNSNotification of Full Year Results
20th Nov 20252:14 pmRNSHolding(s) in Company
4th Nov 20257:07 amRNSDirectorate Update
8th Oct 20257:00 amRNSFurther Issue of Shares and TVR
7th Oct 20257:00 amRNSFull Year Trading Update
1st Oct 20252:15 pmRNSHolding(s) in Company
21st Jul 20257:00 amRNSChief Financial Officer Transition
15th Jul 20255:08 pmRNSHolding(s) in Company
30th Jun 20257:00 amRNSNotification of Major Holdings
23rd Jun 20252:30 pmRNSHolding(s) in Company - Replacement
20th Jun 202512:08 pmRNSHolding(s) in Company
18th Jun 20257:00 amRNSCompletion of Acquisition & Total Voting Rights
3rd Jun 20257:00 amRNSInterim Results
20th May 20257:00 amRNSNotification of Half Year Results
14th May 20257:00 amRNSAcquisition of Global Photonics
9th Apr 20252:16 pmRNSHolding(s) in Company
8th Apr 20257:00 amRNSHalf Year Trading Update
24th Feb 20252:19 pmRNSResult of AGM
24th Feb 20257:00 amRNSAGM Trading Update
7th Jan 20252:58 pmRNSGrant of LTIP Awards
6th Jan 202511:15 amRNSPosting of Annual Report and Notice of AGM
20th Dec 20243:15 pmRNSHolding(s) in Company
3rd Dec 20247:00 amRNSResults for the year ended 30 September 2024
4th Nov 20247:00 amRNSNotification of Full Year Results
30th Oct 20247:00 amRNSAcquisition of Phoenix Optical
28th Oct 20242:35 pmRNSHolding(s) in Company
8th Oct 20247:00 amRNSFull Year Trading Update
26th Sep 202410:31 amRNSDirector/PDMR Shareholding
23rd Aug 202412:52 pmRNSNotification of Major Holdings
16th Aug 20245:46 pmRNSHolding(s) in Company
16th Aug 20244:49 pmRNSHolding(s) in Company
15th Aug 20244:33 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.